The FDA is reviewing durvalumab with enfortumab vedotin for patients with muscle-invasive bladder cancer who cannot receive ...

A little-known system determines what surgeries are worth. It almost always values men more highly.

A retrospective cohort of 186 patients with seromucinous borderline ovarian tumors found that cystectomy and unilateral ...

American Society for Radiation Oncology (ASTRO) published its first clinical practice guideline on radiation therapy for ...

Biodesign brings clinicians, engineers, and other experts together to address real clinical needs, while accounting for regulatory, financial and workflow barriers.

Enfortumab vedotin-pembrolizumab shows durability advantage over chemotherapy at three-year follow-up in bladder cancer trial ...

Bladder and Urothelial Cancer Trials to Watch at ESMO 2026 / bladder cancer, cancer, cancer care, Cancer research, cancer ...

A Barcelona study of 87 patients shows that FGFR3 protein overexpression independently predicts recurrence in high-grade T1 ...

August–September 2026 / bladder cancer, cancer, cancer care, Cancer research, cancer treatment, chemotherapy, clinical trials ...

AstraZeneca?s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in combination with enfortumab vedotin (EV) was accepted and granted Priority Review in the US for the ...

The two universities collaborate on addressing disparities in healthcare, accelerating scientific and medical innovation, and ...

Sarah Schmelzel fought a 15-year battle for a diagnosis of Stage IV endometriosis and after multiple surgeries, the 31-year-old LPGA Tour player is looking to return to the game she loves next year.